Clinical trials · San Francisco, CA
Cardiomyopathies clinical trials in San Francisco
We’re tracking 26 recruiting cardiomyopathies studies with a site in or near San Francisco — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near San Francisco
- NCT07210723RecruitingPhase 2/Phase 3
Study of danicamtiv for genetic and familial dilated cardiomyopathy
This trial tests if danicamtiv can improve heart function in people with dilated cardiomyopathy caused by certain genetic changes. It may help those who have stable symptoms but still need more treatment options.
San Francisco, CaliforniaAges 18 years+ - NCT06311708Recruiting
PKP2-related heart condition natural history study
This study looks at how plakophilin 2 (PKP2)-related arrhythmogenic right ventricular cardiomyopathy (ARVC) progresses over time. You'll give blood samples to check for antibodies to a virus used in gene therapy, and help doctors understand the disease better.
San Francisco, CaliforniaAges 14–65 - NCT05034432RecruitingPhase 4
Test treatment for dangerous heart rhythm episodes in LVAD patients
This trial studies a procedure to fix abnormal heart rhythms (ventricular tachycardia or ventricular fibrillation) in people who have an LVAD and a defibrillator (ICD) or an alternative device. It may help prevent future dangerous rhythm episodes after LVAD treatment.
San Francisco, CaliforniaAges 18 years+ - NCT04520347Enrolling by invitation
Registry for heart rhythm ablation in VT or PVC
This study is a “registry,” meaning it collects information about people undergoing a procedure to treat abnormal heart rhythms like ventricular tachycardia (VT) or premature ventricular contractions (PVCs). It may help researchers better understand which patients benefit from the procedure and how it is done over time.
San Francisco, CaliforniaAges Any age - NCT07207811RecruitingPhase 3
Coramitug for heart failure caused by ATTR amyloidosis
This trial tests a new medicine called Coramitug for people with heart failure due to ATTR amyloidosis, a condition where abnormal proteins build up in the heart. The study aims to see if Coramitug can improve heart function and quality of life.
San Francisco, CaliforniaAges 18 years+ - NCT06228924RecruitingPhase 1
Gene therapy for ARVC with PKP2 mutation
This trial tests a new gene therapy called TN-401 for people with ARVC caused by a specific PKP2 gene mutation. The goal is to see if the treatment is safe and can help reduce dangerous heart rhythms.
San Francisco, CaliforniaAges 18–65 - NCT06563895RecruitingPhase 3
Testing acoramidis to prevent ATTR amyloidosis in gene carriers
This trial tests a daily pill called acoramidis to see if it can prevent ATTR amyloidosis in people who carry a gene mutation but have no symptoms yet. It aims to stop the disease before it starts.
San Francisco, CaliforniaAges 18–75 - NCT04848506Enrolling by invitationPhase 2/Phase 3
Long-term safety follow-up with aficamten for adults with HCM
This study checks how safe and well-tolerated aficamten is over the long run in adults with hypertrophic cardiomyopathy (HCM). You may be eligible if you finished a prior Cytokinetics aficamten study and your heart pumping strength is in the required range.
San Francisco, CaliforniaAges 18–85 - NCT05836259RecruitingPhase 1/Phase 2
TN-201 for heart symptoms from MYBPC3 heart disease
This early trial tests TN-201 to see how safe it is and how well it works to reduce symptoms in adults with MYBPC3-related hypertrophic cardiomyopathy. It’s designed to learn safe dosing, and you may be eligible if you have specific genetic heart changes and ongoing symptoms.
San Francisco, CaliforniaAges 18–75 - NCT07023614RecruitingPhase 2
Study of Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy
This trial tests an investigational drug (ninerafaxstat) for people with a specific type of thickened heart muscle called non-obstructive hypertrophic cardiomyopathy. The goal is to see if the drug can improve symptoms and exercise ability.
San Francisco, CaliforniaAges 18 years+ - NCT05667493Enrolling by invitationPhase 3
Long-term safety follow-up for eplontersen in ATTR heart disease
This is a long-term study to check the safety of eplontersen over time in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). It is mainly for people who already took the study medication before, or who joined an earlier related study and are doing well.
San Francisco, CaliforniaAges 18 years+ - NCT05489705Recruiting
Real-world registry for mavacamten and other obstructive HCM treatments
This study collects real-world information about people with obstructive hypertrophic cardiomyopathy (HCM) who are being treated with mavacamten or other standard medicines. It aims to understand patient characteristics, treatment choices over time, and long-term outcomes.
San Francisco, CaliforniaAges 18 years+ - NCT05818605Recruiting
Exercise training for people with hypertrophic heart muscle
This study tests whether a 24-week exercise program can improve exercise tolerance in people with hypertrophic cardiomyopathy (a thickened heart muscle). You may be asked to use phone-based tools and complete surveys during training.
San Francisco, CaliforniaAges 18–80 - NCT01790152Recruiting
Dexrazoxane study to monitor heart damage in cancer survivors
This study tests dexrazoxane (DRZ) to see how it affects blood and heart-related “biomarkers,” or measurable signs of heart damage, after cancer treatment. It mainly targets survivors who may be at risk for cardiomyopathy (heart muscle weakness) or related heart failure.
Oakland, CaliforniaAges Any age - NCT06976606Recruiting
A study of adults with PKP2-linked arrhythmogenic cardiomyopathy
This study follows people with a confirmed PKP2 genetic mutation and arrhythmogenic cardiomyopathy (ACM) to understand how their condition changes over time. It may help doctors learn more about the disease and plan future treatments.
Redwood City, CaliforniaAges 18–65 - NCT06128629RecruitingPhase 3
A study of NTLA-2001 for transthyretin amyloidosis with heart problems
This study tests a new treatment, NTLA-2001, for people with a type of heart disease called transthyretin amyloidosis with cardiomyopathy. It aims to see if the medicine can help improve heart function and quality of life.
Palo Alto, CaliforniaAges 18–90 - NCT07218887RecruitingPhase 1/Phase 2
Gene therapy for BAG3-related heart failure
This study tests an experimental gene therapy called ALXN2350 for people with dilated cardiomyopathy caused by a specific genetic change in the BAG3 gene. It aims to see if the therapy can improve heart function and slow disease progression.
Palo Alto, CaliforniaAges 18–70 - NCT06080074RecruitingPhase 2
Emergency heart-lung machine study for children with severe heart failure
This study tests a specific heart-lung machine called Cardiohelp to help children with severe heart failure. It looks at how well the machine works and whether a blood thinner (either heparin or bivalirudin) is safer and more effective.
Palo Alto, CaliforniaAges birth–16 years - NCT07690436Recruiting
Eye imaging for detecting a type of heart disease
This study uses retinal imaging (pictures of the back of the eye) and OCT scans to look for signs of a specific heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). It may help doctors find this condition with an eye exam instead of more invasive tests.
Palo Alto, CaliforniaAges 18 years+ - NCT06935253Recruiting
AI to Improve Cardiology Care
This trial tests whether large language models (a type of AI that understands human language) can help cardiologists give better care. If you are a qualified cardiologist who currently treats patients, you may be eligible.
Palo Alto, CaliforniaAges 18 years+ - NCT04476901RecruitingPhase 2
Study of donor stem cell treatment for non-ischemic heart failure
This Phase 2 trial tests whether donor “MSC” cells can improve heart function in people with non-ischemic dilated cardiomyopathy and reduced pumping strength. You may be eligible if your condition is already treated with standard heart medicines and you can safely undergo a heart catheterization and follow-up testing.
Stanford, CaliforniaAges 18–80 - NCT06361524Enrolling by invitation
Gut bacteria study in chronic heart failure
This study looks at the bacteria in your gut (your 'gut microbiome') and how it relates to chronic heart failure. It may help doctors understand why some people with heart failure do better than others and could lead to better treatments in the future.
Stanford, CaliforniaAges 18–75 - NCT07052903RecruitingPhase 3
RNA therapy for ATTR amyloidosis with heart involvement
This trial tests an experimental RNA therapy (nucresiran) for people with transthyretin amyloidosis that causes heart problems (cardiomyopathy). It aims to lower the abnormal protein buildup to help heart function.
Stanford, CaliforniaAges 18–85 - NCT06679946Enrolling by invitationPhase 3
Study of Vutrisiran for heart condition from TTR amyloidosis
This study tests a drug called vutrisiran for people with a condition called transthyretin amyloidosis that affects the heart. It is for patients who have already been in certain earlier studies of patisiran or vutrisiran.
Stanford, CaliforniaAges 18 years+
Hear when a new Cardiomyopathies trial opens near San Francisco, CA
We’ll email you when one opens near San Francisco, CA — at most once a week, no account needed, unsubscribe anytime.
Cardiomyopathies trials in other cities
Where these studies are running near San Francisco
Institutions with a site for the recruiting cardiomyopathies studies listed above.
- University of California, San Francisco · 11 studies
- Stanford University · 6 studies
- Clinical Trial Site · 2 studies
- Lucile Packard Children's Hospital at Stanford · 2 studies
- Research Site · 2 studies
- Imbria Investigational Site
- Kaiser Permanente-Oakland
- Leland Stanford Junior University
What taking part in a cardiomyopathies study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting cardiomyopathies studies in California.
Common questions
- Are there cardiomyopathies clinical trials near San Francisco?
- Yes. We're currently tracking 26 recruiting cardiomyopathies studies with a site near San Francisco, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cardiomyopathies study near San Francisco?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in San Francisco to take part?
- Not necessarily. These studies have a site near San Francisco, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cardiomyopathies trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cardiomyopathies studies open near San Francisco regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.